Three-Year Switch Exclusivity Included In Amended EU Drug Legislation
This article was originally published in The Tan Sheet
Executive Summary
Three years of data exclusivity for Rx-to-OTC switch candidates and new indications of approved medicinal products would be available to European drug marketers under legislation currently making its way through the European regulatory process
You may also be interested in...
Should Unqualified Health Claims Sound Less Tentative? FDA Seeks Input
FDA is requesting additional comments on whether the words "may" or "might" should be removed from unqualified health claims to avoid consumer confusion about the science substantiating the claim
EU Revised Legislation Provides One-Year Exclusivity For OTC Switches
Rx-to-OTC switches in the European Union will be provided one year of data exclusivity, instead of the previously proposed three-year period, in a proposed amendment to EU pharmaceutical legislation recently approved by the European Parliament
Herbal/Non-Herbal Combos Addressed In EU Parliamentary Amendments
Requirements stipulating herbal products be sold with labeling or leaflets stating they have "not been clinically proven" would be removed under an amendment to the Traditional Herbal Medicinal Products Directive approved by the European Parliament